You cannot purchase a generic Prolensa (bromfenac) product at this time, as this drug is protected by certain patents that prevent companies from making a generic version of this medicated eye drop. The first patent is scheduled to expire in September 2025. This is the earliest predictable date that a generic version of Prolensa might become available.
Prolensa is made by Bausch & Lomb Incorporated. It is currently under the protection of a patent that prevents any generic versions from being manufactured in the United States.
When Will a Generic Version Be Available?
The first patent for Prolensa is set to expire in September 2025. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Prolensa uses. Once Prolensa goes off-patent, there may be several companies that manufacture a generic version of Prolensa.
Is Bromfenac a Generic Prolensa?
No -- bromfenac is the active ingredient in Prolensa, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer would make the product.
It is worthwhile to note that bromfenac is also the active ingredient in other eye drop medications. Bromday® is a brand-name eye drop product containing a higher concentration of bromfenac (0.09% ophthalmic solution). Bromday is available in generic form.
Xibrom® was another brand-name medicine that contained bromfenac (also 0.09% ophthalmic solution). The manufacturer of Xibrom stopped making the medication, and it is no longer available. However, generic versions of Xibrom are still available. Like Prolensa, Bromday and generic Xibrom are approved to reduce inflammation and pain after cataract surgery.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed February 6, 2014.
Bromfenac. Drug Facts and Comparisons. Drug Facts and Comparisons 4.0 [online]. 2013. Available from Wolters Kluwer Health, Inc. Accessed May 7, 2013.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click